Nottingham IBD study testing new treatments
Part of Digestive system clinical trials.
This study looks at people with active Crohn's disease or ulcerative colitis starting a new type of medication (anti-TNF, ustekinumab, upadacitinib, or vedolizumab), as well as people without IBD having a routine colonoscopy. It aims to collect information to better understand how these treatments work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 16 years old.
- If you have Crohn's disease: you must have active inflammation (based on blood or stool tests, or visible ulcers on a scope or imaging) and be starting a new treatment like anti-TNF, ustekinumab, or upadacitinib.
- If you have ulcerative colitis: you must have active inflammation (based on blood or stool tests, or visible findings on a scope) and be starting a new treatment like anti-TNF or vedolizumab.
- If you do not have IBD: you must be scheduled for a lower GI colonoscopy and have no bowel disease found.
- You cannot have active infections (including hepatitis B, C, HIV, or COVID), a current cancer diagnosis, or be pregnant.
- You must not have had a transfusion of blood products in the last 120 days or taken part in another drug study in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults with Crohn’s disease or ulcerative colitis when their treatment is changed. It collects health information and samples to better understand how treatment changes affect people over time.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
This study is for children and teens with inflammatory bowel disease (Crohn's, colitis, or indeterminate) whose previous anti-TNF medicine stopped working. It compares several newer treatments to see which works best.
This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.
Hear when a new Gastro-Intestinal Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.